Viewing Study NCT05236257

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:52 PM
Ignite Modification Date: 2026-06-08 @ 3:29 PM
Study NCT ID: NCT05236257
Status: COMPLETED
Last Update Posted: 2024-12-10
First Post: 2022-02-02
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database
Sponsor: Bayer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene … View
None Infantile Fibrosarcoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced solid tumors View
None Infantile fibrosarcoma (IFS) View
None Neurotrophic tyrosine receptor kinase (NTRK) View
None Fusion Positive View
None Tropomyosin Receptor Kinase (TRK) fusion View
None Larotrectinib View
None External control View